March 25, 2016. NCHR strongly supports the safety and effectiveness clinical and nonclinical testing requirements to obtain generally recognized as safe and effective (GRASE) status, as they are delineated in the draft guidance. The proposed testing requirements for new sunscreen chemicals will assure our country’s most vulnerable that the products will protect them from skin cancer and not cause unintended harm.
Read More »On Health Policy
NCHR Flu Vaccine Testimony
March 4, 2016. We applaud the FDA and CDC for changing the recommendations for children, to reflect the poor efficacy of the live attenuated influenza vaccine (nasal spray). There is another problem however, that I want to talk about today. The CDC has strongly encouraged patients to use antiviral medications if they get the flu. However, the evidence shows how little benefit Tamiflu offers, as well as significant risks for children.
Read More »Patient, Consumer, and Public Health Coalition Senate Briefing: Innovation for Healthier Americans
March 4, 2016. These are the materials from the Senate briefing we hosted on March 4, 2016 with the Patient, Consumer, and Public Health Coalition titled “Innovation for Healthier Americans: The Impact of Proposed Health Bills on Patients & Consumers”.
Read More »Letter to HELP Committee Re: Innovation Bills
March 5, 2016. This letter from the Patient, Consumer, and Public Health Coalition expresses disappointment that these bills are so biased against the interests of nonprofit member organizations, who represent millions of patients, consumers, scientists, and public health researchers and advocates.
Read More »NCHR Testimony at 2016 FDA Public Meeting on Demographic Subgroup Data
February 29, 2016. The FDA should make it clear that the agency will not approve medical products for all populations if the sponsor has not tested the product for safety and effectiveness on all major demographic subgroups and provided meaningful subgroup analyses.
Read More »